Akttyva Therapeutics, Inc.
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • News
  • Investors
  • About us
  • Join our team
  • Publications
  • Contact
  • More
    • Home
    • News
    • Investors
    • About us
    • Join our team
    • Publications
    • Contact
Akttyva Therapeutics, Inc.

Signed in as:

filler@godaddy.com

  • Home
  • News
  • Investors
  • About us
  • Join our team
  • Publications
  • Contact

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Site Content

Akttyva Therapeutics launches funding campaign

March 12, 2021 Akttyva Therapeutics has launched a crowdfunding campaign to accelerate the development of our lead compound for ARDS patients and to launch additional programs. You can own a part of our company and join us on this exciting journey. Here is how:   https://fundify.com/s/akttyva-therapeutics/

Akttyva Therapeutics gets NSF award

 December 14, 2021 Honored to announce a National Science Foundation (NSF) award to  further develop and commercialize our AIDE-360 platform that aims at facilitating the  rational design of therapeutics addressing vascular leak disorders. This highly competitive award is a demonstration of innovative nature and commercial potential, the two main criteria for NSF grant review. This grant will allow us to accelerate the 2nd generation AIDE-360 and develop the commercialization plan. More about the program: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136307&HistoricalAwards=false

Akttyva Therapeutics gets NSF award

 December 14, 2021 Honored to announce a National Science Foundation (NSF) award to  further develop and commercialize our AIDE-360 platform that aims at facilitating the  rational design of therapeutics addressing vascular leak disorders. This highly competitive award is a demonstration of innovative nature and commercial potential, the two main criteria for NSF grant review. This grant will allow us to accelerate the 2nd generation AIDE-360 and develop the commercialization plan. More about the program: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2136307&HistoricalAwards=false

akttyva won an ibm prize

 November 17, 2021. Akttyva  Therapeutics won an IBM  prize for its AI drug-discovery program AIDE-360, which was used to discover the hits for the vascular leak program

Akttyva is a finalist of masschallenge

 October 1, 2021. Akttyva  Therapeutics is a finalist of the highly selective 2021 MassChallenge  competition! We are honored to be one of only 45 companies out of 229  selected for the final round (out of over 3,000 original applications).  The winners of the final round will compete for $1M non-dilutive cash  prizes competition

https://readymag.com/MassChallenge/Finalists21/finalists/

akttyva opens laboratories

April 1, 2021 Akttyva has established laboratories in Mansfield Bioincubator

Dr. Mario dipaola joins the team

January 10, 2021 Dr. Mario DiPaola, an experienced scientist and successful entrepreneur, joins Akttyva as Head of Research.

Copyright © 2022 Akttyva Therapeutics - All Rights Reserved.

  • About us
  • Contact